0
Diffuse Lung Disease: Diffuse Lung Disease: Interstitial Lung Disease |

Erythropoietin Inhibits the Immunohistochemical Expression of Lysyl Oxidase in Bleomycin-Induced Pulmonary Fibrosis in Rats FREE TO VIEW

Drosos Tsavlis, PhD; Sofia Tsirona, MD; Fotios Katsaros, MD; Anastasia Tektonidou, MMSc; Anna Tzoumaka, MD
Author and Funding Information

Aristotle University of Thessaloniki, Thessaloniki, Greece


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A211. doi:10.1016/j.chest.2016.02.218
Text Size: A A A
Published online

SESSION TITLE: Diffuse Lung Disease: Interstitial Lung Disease

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Pulmonary Fibrosis (PF) is characterized by fibroblasts' proliferation, excessive deposition of collagen and extracellular matrix remodelling. The enzyme Lysyl Oxidase (LOX) is well known for its important role in the fibrotic pathway with inflammatory and apoptotic actions. Erythropoietin (EPO), on the other hand, is a multiple functional cytokine with anti-inflammatory and anti-apoptotic properties. The purpose of this study was to investigate the role of EPO on the immunohistochemical expression of LOX in Bleomycin (BLM)-induced PF in rats.

METHODS: Fifty Wistar rats (300g) were devided into five groups of ten animals each:1) Group 1:control group, 2) Group 2:intratracheal (it) and intraperitoneal (ip) injection of saline (0.5 ml/kg), 3) Group 3:intratracheal BLM injection (7.5 mg/kg), 4) Group 4:intratracheal BLM injection (7.5 mg/kg) followed by intraperitoneal EPO injection (2000 iu/kg) and finally 5) Group 5:intratracheal injection of saline (0.5ml/kg) and intraperitoneal EPO injection (2000 iu/kg). All rats were sacrificed after 14 days. Histological evaluation was performed on paraffin sections stained with hematoxyline-eosin and lung injury was estimated quantitatively in 15 randomly selected fields/slide by Image Pro Plus software version 4.1. Immunohistochemical evaluation was performed for the expression of LOX. A scale of 4 grades was used for the evaluation of the results: Grade A: 0-25%, Grade B: 25-50%, Grade C: 50-75% and Grade D: 75-100%

RESULTS: In groups 1,2 and 5 (control groups) the tissue damage was extremely little and LOX was expressed only in the two lower grades of the scale (A:90% and B:10%). In group 3 (BLM group) the lung tissue damage was very extended and LOX was expressed in the high grades (C:20% and D:80%). Finally, in group 4 (BLM+EPO group) the lung tissue damage was little and similar to the control groups' damage. Moreover, the enzyme in question was expressed only in the two low grades (A:80% and B:20%). The expression of LOX took place in the high grades for group 3 (BLM group) and in the lower grades for group 4 (BLM+EPO group) (p<0.001 and p<0.05 respectively).

CONCLUSIONS: Treatment with EPO significantly ameliorated the extent and severity of the BLM-induced toxicity in lung tissue. LOX had a significantly lower expression in the group of animals which were administrated with EPO, compared to the group of animals treated only with BLM.

CLINICAL IMPLICATIONS: Additional studies are required to clarify the underlying mechanisms of the protective action of EPO on lung fibrosis.

DISCLOSURE: The following authors have nothing to disclose: Drosos Tsavlis, Sofia Tsirona, Fotios Katsaros, Anastasia Tektonidou, Anna Tzoumaka

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543